Alaunos Therapeutics, INC DEF 14A proxy statements

Alaunos Therapeutics is holding its 2025 Annual Meeting to vote on key proposals including director elections, auditor ratification, executive compensation, a potential reverse stock split, increased share authorization, and an amendment to the equity incentive plan.

Alaunos Therapeutics is asking stockholders to approve several key proposals at its upcoming annual meeting, including a reverse stock split, an increase in authorized shares, and an amendment to its equity incentive plan.

Alaunos Therapeutics is asking stockholders to vote on key proposals at its upcoming annual meeting, including a reverse stock split and an increase in authorized shares.

Alaunos Therapeutics is asking stockholders to approve a reverse stock split and an increase in authorized shares at its upcoming annual meeting to maintain Nasdaq listing and provide financial flexibility.